BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 27076286)

  • 1. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
    Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
    Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
    Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
    Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding.
    Cabral KP; Fraser GL; Duprey J; Gibbons BA; Hayes T; Florman JE; Seder DB
    Clin Neurol Neurosurg; 2013 Jun; 115(6):770-4. PubMed ID: 22835715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
    Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
    West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-Factor Versus Four-Factor Prothrombin Complex Concentrate for the Emergent Management of Warfarin-Associated Intracranial Hemorrhage.
    Fischer D; Sorensen J; Fontaine GV
    Neurocrit Care; 2018 Feb; 28(1):43-50. PubMed ID: 28612131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
    Pinner NA; Hurdle AC; Oliphant C; Reaves A; Lobo B; Sills A
    World Neurosurg; 2010 Dec; 74(6):631-5. PubMed ID: 21492631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
    Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
    Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
    Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
    J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Effectiveness of Factor VIII Inhibitor Bypassing Activity (FEIBA) and Fresh Frozen Plasma in Oral Anticoagulant-Associated Intracranial Hemorrhage: A Retrospective Analysis.
    Yin EB; Tan B; Nguyen T; Salazar M; Putney K; Gupta P; Suarez JI; Bershad EM
    Neurocrit Care; 2017 Aug; 27(1):51-59. PubMed ID: 28243997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
    Yohe AS; Livings SE
    Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage.
    Chu C; Tokumaru S; Izumi K; Nakagawa K
    Int J Neurosci; 2016; 126(1):62-6. PubMed ID: 25430740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
    Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
    Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Venous Thromboembolism After Receiving Prothrombin Complex Concentrate for Warfarin-associated Intracranial Hemorrhage.
    Felton D; Foley EM; Traub SJ; Vodonos A; Ganetsky M
    J Emerg Med; 2016 Jan; 50(1):1-6. PubMed ID: 26409668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new kid on the block: Outcomes with Kcentra 1 year after approval.
    Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
    J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.